Novo co-led an $81.5m round for the gene therapy developer that included Sarepta Therapeutics, UCB Ventures, Takeda Ventures and Alexandria Venture Investments.
US-based gene therapy developer StrideBio closed an $81.5m series B round yesterday co-led by pharmaceutical firm Novo and venture capital firm Northpond Ventures.
The round included pharmaceutical companies Sarepta Therapeutics, UCB and Takeda, the last two investing through their UCB Ventures and Takeda Ventures vehicles, while real estate investment trust Alexandria Real Estate Equities took part through Alexandria Venture Investments.
University of Florida’s UF Innovate Ventures filled out the round together with Pontifax, Octagon Capital, CaaS Capital and Hatteras Venture…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
